Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Published	Pages	Publisher	Report code
Nov 2022	67	Global Markets Direct	ASDR-613185

Published: Nov 2022 - Pages : 67 - Publisher : Global Markets Direct - Report code : ASDR-613185

180 Life Sciences Corp
AlphaCognition Inc
AstraZeneca Plc
Bionomics Ltd
Bristol-Myers Squibb Co
DanPET AB
Epigen Biosciences Inc
Lupin Ltd
Merck & Co Inc
Neuro Bio Ltd
Serenity Bioworks Inc
SK Life Science Inc
Vanda Pharmaceuticals Inc

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

This report can be of interest as well:

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) Drugs in Development by Therapy Areas and Indications, Stages, M...

Published: May, 2022 | Report code: ASDR-601524